IP Library › Granted Patent US 12,630,535
Granted Patent B2
US 12,630,535 · App. 18/021,308 · Granted May 19, 2026

Inhibitors of ACK1/TNK2 tyrosine kinase

Inventors: Nicholas J. Lawrence (Lutz, FL); Harshani Rithma Lawrence (Lutz, FL); Derek Duckett (Land O Lakes, FL); Gary Reuther (Temple Terrace, FL)
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
C07D403/12A61K45/06C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,630,535
App. No.
18/021,308
Granted
May 19, 2026
Kind
B2
Abstract

The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.

Claims (16)

1 . A compound selected from:

or a pharmaceutically acceptable salt thereof.

2 . A compound selected from:

or a pharmaceutically acceptable salt thereof.

3 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4 . A method of treating a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , further comprising administering an additional therapeutic agent.

6 . The method of claim 5 , wherein the additional therapeutic agent comprises an anti-cancer agent or an anti-inflammatory agent.

7 . The method of claim 4 , further comprising administering an effective amount of ionizing radiation to the subject.

8 . A method of killing a tumor cell comprising contacting the tumor cell with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

9 . A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10 . A method of treating a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

11 . The method of claim 10 , further comprising administering an additional therapeutic agent.

12 . The method of claim 11 , wherein the additional therapeutic agent comprises an anti-cancer agent or an anti-inflammatory agent.

13 . The method of claim 10 , further comprising administering an effective amount of ionizing radiation to the subject.

14 . A method of killing a tumor cell comprising contacting the tumor cell with an effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
LICENSE Recorded Aug 12, 2024
From: H. LEE MOFFITT CANCER CTR & RES INST
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068551/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2023
From: LAWRENCE, NICHOLAS J.; LAWRENCE, HARSHANI RITHMA; DUCKETT, DEREK; REUTHER, GARY
To: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Reel/Frame 064498/0716 →
Continuity (3)
Provisional Application 63229392 · Aug 4, 2021
Provisional Application 63065766 · Aug 14, 2020
Related Publication 20230295129A1 · Sep 21, 2023
References Cited (65)
US 4559157A · Smith et al. · 1985 [cited by applicant]
US 4608392A · Jacquet et al. · 1986 [cited by applicant]
US 4820508A · Wortzman · 1989 [cited by applicant]
US 4938949A · Borch et al. · 1990 [cited by applicant]
US 4992478A · Geria · 1991 [cited by applicant]
US 5167649A · Zook · 1992 [cited by applicant]
US 6960648B2 · Bonny · 2005 [cited by applicant]
US 9464091B2 · Gray et al. · 2016 [cited by applicant]
US 9850216B2 · Mahajan · 2017 [cited by examiner]
US 10336734B2 · Mahajan · 2019 [cited by examiner]
US 20020035243A1 · Imfeld et al. · 2002 [cited by applicant]
US 20020120100A1 · Bonny · 2002 [cited by applicant]
US 20030032594A1 · Bonny · 2003 [cited by applicant]
US 20170044111A1 · Gray et al. · 2017 [cited by applicant]
US 20180215738A1 · Mahajan et al. · 2018 [cited by applicant]
US 20190315726A1 · Lee et al. · 2019 [cited by applicant]
CN 105017160 · 2017 [cited by applicant]
CN 105017160B · 2017 [cited by examiner]
WO 2010055117 · 2010 [cited by applicant]
WO 2015021149 · 2015 [cited by applicant]
WO 2017023899 · 2017 [cited by applicant]
WO 2017066428 · 2017 [cited by applicant]
WO 2020051572 · 2020 [cited by applicant]
WO 2022036310 · 2022 [cited by applicant]
WO 2022036313 · 2022 [cited by applicant]
Machine Translation of CN105017160B spec (Year: 2017). [cited by examiner]
Mahajan K, et al. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Lett. 2013; 338:185-92. [cited by applicant]
Mahajan K, et al. Shepherding AKT and androgen receptor by ACK1 tyrosine kinase. [cited by applicant]
Mahajan K, et al. Activated Cdc42-associated kinase ACK1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. [cited by applicant]
Mahajan K, et al. ACK1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. [cited by applicant]
Aqeilan Ri, et al. WWOX in biological control and tumorigenesis. [cited by applicant]
Mahajan K, et al. Activated tyrosine kinase ACK1 promotes prostate tumorigenesis: role of ACK1 in polyubiquitination of tumor suppressor Wwox. [cited by applicant]
Franke TF, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. [cited by applicant]
Burgering BM, et al .Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. [cited by applicant]
Manning BD, et al. AKT/PKB signaling: navigating downstream. [cited by applicant]
Mahajan K, et al. ACK1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. [cited by applicant]
DiMauro EF, et al. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. [cited by applicant]
Martin MW, et al. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. [cited by applicant]
Mahajan K, et al. ACK1 tyrosine kinase activation correlates with pancreatic cancer progression. [cited by applicant]
Mahajan K, et al. Effect of ACK1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. [cited by applicant]
Kopecky DJ, et al. Identification and optimization of N3,N6-diaryl-1Hpyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors. [cited by applicant]
Miduturu CV, et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. [cited by applicant]
Jin M, et al. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. [cited by applicant]
Golas JM, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K56… [cited by applicant]
Remsing R, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. [cited by applicant]
Tan DS, et al. Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer. [cited by applicant]
Carter TA, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. [cited by applicant]
Liu Y, et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by ACK1 and Src kinases. [cited by applicant]
Li J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. [cited by applicant]
Galkin AV, et al. Identification of NVP-TAE684, a potent, selective, and 20 efficacious inhibitor of NPM-ALK. [cited by applicant]
Davis MI, et al. Comprehensive analysis of kinase inhibitor selectivity. [cited by applicant]
Metz JT, et al. Navigating the kinome. [cited by applicant]
Jiao X, et al. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors. [cited by applicant]
Bossi RT, et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. [cited by applicant]
Bebbington D, et al. The discovery of the potent aurora inhibitor MK-0457 (VX-680). [cited by applicant]
Moriarty KJ, et al. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora—A kinase inhibitors. [cited by applicant]
Tari LW, et al. Structural basis for 5 the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. [cited by applicant]
Lawrence HR, et al. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. [cited by applicant]
Martin MP, et al. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. [cited by applicant]
Yang H, et al. Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation. [cited by applicant]
Toyoizumi, et al., “Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer,” [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/046116 dated Feb. 1, 2022, 10 pages. [cited by applicant]
Tan et al., Development of Selective Covalent Janus Kinase 3 Inhibitors, Journal of Medicinal Chemistry, Aug. 10, 2015, vol. 58, pp. 6589-6606. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/046112 dated Jan. 31, 2022, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/046117 dated Nov. 22, 2021, 12 pages. [cited by applicant]